Lung cancer tissue study on immunotherapy resistance
Part of Cancer, Lungs & breathing clinical trials.
This study looks at preserved tissue samples from people with lung cancer to understand why some tumors don't respond to immunotherapy drugs like PD-1/PD-L1 inhibitors. The goal is to find patterns that could help predict treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery alone for early-stage lung cancer, or you had chemo and radiation followed by durvalumab for stage III lung cancer.
- Your treatment happened between September 2018 and December 2021.
- You have not had another cancer before this one.
- You did not get chemotherapy, radiation, or immunotherapy before your main treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study looks at genetic information from tumor tissue of people with non-small cell lung cancer who had immunotherapy before surgery but still had some cancer cells left. The goal is to understand why the cancer did not completely respond to treatment.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study looks at lung cancer tissue and immune system changes to understand how and why immunotherapy resistance develops. It may help researchers find better ways to make immunotherapy work longer for future patients.
This trial tests how well a new imaging method and lab-grown tumor models can predict response to immunotherapy in people with non-small cell lung cancer that has returned after initial surgery. Participants will receive standard immunotherapy, and researchers will study their tumor samples and scans.
Hear when a new Lung Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.